Replay available

Health X Platform (NSE:HEALTHX) Q1 2027 Earnings Call

Health X Platform (NSE:HEALTHX) Q1 2027 earnings call, held 2026-08-11. Watch the replay and read the transcript on 6ix.

Tue, August 11, 2026 at 9:38 AMendedReplay
Health X Platform (NSE:HEALTHX) Q1 2027 Earnings Call
Company
Health X Platform Ltd (NSE:HEALTHX)
Period
Q1 2027 earnings call
Date
Tue, Aug 11, 2026, 9:38 AM ET
Replay
Watch the replay on this page · 57 min

On 6ix: 6ix.com/event/health-x-platform-limited-healthx-q1-2027-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:00 Ladies and gentlemen, good day, and welcome to Health X Platform Limited q one and FY twenty seven earning conference call hosted by Go India Advisors. As a reminder, all participant line will be in the listen only mode, and there will be an opportunity for you to ask question after the presentation conclude. Please note that this conference is being recorded. I now hand the conference over to miss Soumya from Go India adviser. Thank you, and over to you, Soumya. Hi, everyone. I welcome you all to Health X Platform Limited q one FY twenty seven earnings call call. Please note that discussion on today's call may include certain forward looking statements and must be therefore viewed in conjunction with the risk pertaining to the business. We have on call today mister, the managing director and CEO, and Mr. Lokey Shagarwal, the CFO.

0:55 I now request the management to proceed with the opening remarks. Post that, we'll open the floor for Q and A. Thank you, and over to you, sir. Good afternoon, friends. I'm B. L. Mittal. Welcome to the Health X Platform Limited Q1 FY 'twenty seven Earnings and Business Update Call. We sincerely appreciate your continued touch and support as we build Health X into a technology lead, capital efficient health care platform with a clear objective of making health care more affordable, accessible and trustworthy across India. Q1 FY 'twenty seven has been an increasing start to the year for us. The initiative that we have invested in during the previous year across the Telescope the geographical expansion, fulfillment infrastructure technology and Ditto are now beginning to translate into stronger revenue momentum, while we continue to work towards improving the underlying economics of the business, building a scale with a strong operating foundation.

1:57 The strength of our platform today is reflected in the CLV update. We currently serve approximately 5,000 retail pharmacies with more than 50,000 sourced from 1,000 vendors supported by more than three fifty health parties and 500 employees. Importantly, more than 95% of our facilities are sourced directly from pharmaceutical companies without paying any purchase rights, while our purchase remains below 1%. This gives us a strong sourcing and availability advantage as we continue to scale. HEALTHX and SISTA Sundar, both are driving growth now. Our revenue momentum has achieved meaningfully, led by our two core platform. Retail and Satti grew 48% Y o Y, continued to remain our principal growth engine, while Sensa Satti grew 44% Y o Y, reflecting a strong B2C business.

2:52 The quality of this growth is also increasing with a detail safety. 69.4 of business comes from orders about 2542.4% from orders about 5,000, indicating that retailers are increasingly consolidating meaningfully share of their procurement requirements on our platform. This also eliminates the focus on certain customers because their sales are widespread in thousands of customers. Similarly, 69.2% of systems and orders are about 1,000, highlighting a healthy consumer market size, and it also reflects that 30% of orders are going below 1,000, that shows us the capability to serve even the smallest soda.

3:37 Together, this platform provides us with a strong base to deepen customer engagement and build a larger healthcare ecosystem. We are expanding beyond our existing markets, a part of Kotis strategy is to replicate this model across geographies. Building on our existing West Bengal infrastructure, we have expanded into Orissa, Bihar and Jharkhand, while strengthening our northern operation through infrastructure. We already deployed first team and established the logistic and fulfillment capabilities required to penetrate these markets. The early response reinforce our confidence in this strategy. Importantly, our business is not dependent only on large metropolitan market. Approximately 67 of retail electricity business and 78% of sustainable business comes from Tier two and Tier three markets.

4:28 This reinforced our philosophy of inclusive health care infrastructure in India, which the India needs and we provide across geographies, across income level. This demonstrates the scalability of our model and the significant opportunity available in the end of current market where accessibility, affordability and reliability, availability remains important need. Our new initiative, which is getting another growth opportunity that is another strategic initiative at private level to which we aim to make quality health care significantly more affordable by offering medicine at prices of up to 60% lower than leading branded alternatives. We see opportunity to simultaneously improve affordability for customers and create an additional margin opportunity for the platform.

5:19 At this stage, our focus remains on building the right subscription network, establishing customer acceptance and scaling the business in a disciplined manner. We are investing ahead of scale while improving economics. On profitability, EBITDA posted at INR 14.9 crore during the quarter As we continue to invest on team and in technology capabilities across procurement, inventory management and customer engagement, I would like to reiterate that almost all our revenue is contribution margin for consumer revenue. We have consistently maintained that technology investment needs to be made ahead of the scale for capital deployment, but ultimately supported by sound economics. Our objective is therefore to continue investing in capabilities that can provide productivity and customer experience, while progressively moving the platform towards stronger profitability and capital efficiency.

6:16 What paid stood at INR 2 crore, reflecting the improving underlying economics of the business, Technology and fulfillment are also key enablers. Technology remains central to how we intend to scale the platform. We are continuing to strengthening our platform infrastructure and our existing network complemented by new capabilities in Guwahati, Lucknow and Udaipur. These specialties will allow us to penetrate different to the market. We have already entered and improved service level as volumes increase. Our fulfillment centers are becoming increasingly automatic and technology lead, helping us improve throughout inventory management and manpower productivity. At the same time, we remain focused on maintaining a capital efficient model. Our working capital cycle is approximately twenty eight days, equivalent to roughly 8% of revenue is provided with a strong 40% scale, disproportionately increasing our working capital requirement.

7:12 Hence, our company is just an infancy state, but this much I can say that the model is established as one of the highest growing company with most capital efficient requirement. And now I speak about the outlook. Overall, we believe that FY 'twenty seven can be important here for HEALTHX. This quarter is the best quarter in the history of the company. We are ahead of the composite sales with Flipkart partnership that entered and ultimately terminated. This quarter, we closed the highest turnover, which we reported in during our Flipkart partnership era. And this year, we believe that should be the best year in the history of Health X.

8:00 The investment made during the previous year are now coming together. Retail is scaling strongly. Successful is recovering more, geographic footprint is expanding. New fulfillment capabilities are coming online and digital is gradually building momentum. Our focus for the year is clear growth of platform across India, improved technology efficiency and progressive enhanced profitability and capacity efficiency. We are continuously working to launch our AI monitored, retail AI product for our retailers, and we are scheduled to launch in this quarter. Hopefully, in the next quarter, we'll confirm the success of the project. We believe the combination of our customer network sourcing capabilities, technology platform and expanding infrastructure give us a strong foundation to build a large, scalable and sustainable health care platform over the coming years.

8:52 With this, I will now request our CFO, Mr. Loke Sadarwal, to take you through the detailed financial performance for the quarter end June 2026. Mr. Loke Sagarwal. Thank you. Thank you, Mr. Ajith. Good afternoon, everyone. So again, Health X delivered a strong top line momentum in Q1 FY 'twenty seven with revenue from operation growing more than 58 at year on year level to INR $4.40 crores and registering a growth of over 16% on quarter on quarter basis from INR $3.78 crores. Gross profit increased by 64% year on year to INR 34 crore and 24% quarter on quarter, while gross margin improved to 7.8% from 7.3% in quarter four of FY twenty twenty six.

9:42 Operating profitability also improved sequentially with EBITDA loss narrowing to INR 15 crore from INR 20 crore in Q4 FY twenty twenty six and EBITDA margin improving to negative 3.4% from negative 5.5%. Despite this strong revenue growth, EBITDA remained slightly impacted by higher employee and other operating expenses. At PAT level, the company reported a profit of INR 2 crore in Q1 FY twenty twenty seven, marking a significant improvement from negative 13 crore loss in Q4 FY twenty twenty six. Although profitability remained below INR 26 crore that reported in Q1 FY twenty twenty six.

10:29 Overall, the quarter reflects a strong sequential operational improvement with revenue and gross profit accelerating and operating losses narrowing meaningfully. Going forward, the key focus remains on converting this strong momentum and revenue growth into sustainable EBITDA and profitability through operating leverage and tighter cost monitoring and management. As we move forward, we expect the new geographical market, additional fulfillment infrastructure, increasing retail penetration and Sushta Sundar's continued recovery and the gradual scaling of JITO to support further growth. Our focus remains on maintaining right balance between growth, margin improvement and capital efficiency.

11:16 With this, I would like to hand the floor back to the moderator for any question and answer from the perspective. Thank you. Thank you so much, sir. Ladies and gentlemen, we will now begin with the question and answer session. Anyone who wishes to ask a question may press star and 1 on their touch tone telephone. If you wish to remove yourself from the question queue, you may press 2. Participants are request to use handsets while asking a question. Ladies and gentlemen, we'll wait for a moment while the question queue assembles. First question comes from the line of with Robo Capital. Please go ahead. Hi. Thank you for the opportunity. So my question was that for retail, Shakti, what was the gross margin and EBITDA margin in q one FY twenty seven?

12:12 So in Q1 FY twenty twenty seven, at Retailer Shakti, we are maintaining a gross margin of around 7.8% and EBITDA number, we are closer to breakeven and expect to make positive EBITDA in Q3 this financial year end. Okay. And sir, any revenue aspiration for FY 2027 and FY 2028? I mean, as I said that we don't project on yearly basis, but you can I can tell you what happened in May? So May, we ended with INR 150 crore plus revenue. So you're looking to the growth, you can now extrapolate the revenue projection for this year and next year. May we ended with INR 150 crore subject to audit revenue on the ARR.

13:06 All right. That's all from my end. Thank you. Thank you. Our next question comes from the line of Abhishek Singhal with Poverty Duty Funds. Sir, I first wanted to get some perspective around the gross margin potential of the business that we are building. So if you take how is your private labelGITO panning out in terms of percentage of revenue? How that can ramp up and potential impact of that in gross margin? Because if you compare some of the other listed businesses and look at the gross margin there, they have kind of started reporting almost double digit gross margin at the consolidated level, 10%, 11, 12% also.

14:11 So I just want to get some perspective around how this gross margin ramps up for that. And some... Subsequent to that, if you can, you know, provide some clarity around below gross margin, the current cost structures, how that pan out and what kind of an operating leverage that we see in this business flowing through as the numbers of quarters roll by? So if you give some directional context around that, that would really help us understand the business slightly much better than we currently do on the reported numbers. Thank you, Vivek. This is very important question. We also look into these things. So if you see the companies operating in the distribution business, if you see the pharmacy distribution business at gross margin level is a fabulous good business, both in terms of retail and both in terms of wholesale.

15:01 The companies are making good profits and sufficient gross margin, I would say, has healthy margins. Now if you compare the success center with others, then if you compare at the level of because the gross margin is the function of volume, largely volume, how you procure, at what volume you procure at this level, if you compare other companies, what they were doing, then you will find that the Health X Performance is better than any of the competitors. That is number one. And number two is that the gross margin from here is expanded by virtue of one is by volume, second is by increasing your wallet type of the retailer and third is by increasing the private level. So private level Jitto ramp up is I am pretty sure.

15:48 So we launched in the last quarter of financial year twenty six and we sold products of Jitope around twenty five lakhs and this quarter we sold around 79 lakhs. So those are very minor numbers, but the growth is significant and the gross margin is about 50%. So this digital revenue impact will increase the gross margin. And then since we are the digital business, so we increased the wallet share very significantly like selling of devices, like selling of OTC products, like selling of healthcare products, preventive care products of the pharmacies and thereby we increased the gross margin. So the gross margin, if you see the industry level that taken together of both B2B and B2C, we expect to pay now of around 12% going forward.

16:40 And down the line, we don't look at EBITDA because the main problem of the industry is the depreciation. If you see the beautiful companies, they kill the gross margin earned in their depreciation. And the depreciation is the real cost. So we through digital distribution system, we want to eliminate the depreciation cost and interest cost. And straightway come to the functions whereby from the gross margin to the administrative cost, it goes directly to the shareholders' kitty. So similarly, our entire philosophy is that we should do the same kind of business as the industry practices are in a different manner, adding the digital technology capabilities, add the capital efficiency and add the distribution capability, digital distribution capabilities and we are done. So the capital efficiency along with the digital distribution.

17:36 Digital distribution will ensure the growth comes in a rapid automated manner and capital efficiency ensures that there is no depreciation and no interest cost. And from directly sales, it comes to the cash flow. So our focus is not EBITDA, our focus is cash flow from the revenue. Thanks. I hope it is clear, Abhishek. Sir, just to expand a bit more on this gross margin perspective. If I remember correctly, you right now mentioned somewhere around $1.50 crore kind of a revenue for the month of July in your business. Right? That is both retail, Shakti, and and the HealthBody business put together. Right? Yes.

18:23 Yes. Yes. And sir... And and you and you mentioned that 70 lakh was more like a quarterly. So I... What what I want to understand is, sir, that you're talking about JITO at, like, a 50% kind of a gross margin business. So just from a leverage on this perspective, so for example, once your $1.50 crore top line goes to, say, 200 crore a month, in your view, what could the JITO contribution be in this or or or the private label or whatever, like, your own push be in that? And and as 15... So essentially, what I what I'm trying to arrive at is that if, say, your JITO revenue becomes 2% of your monthly sales, it could almost add, like, a 100 basis point kind of a gross margin expansion. Right?

19:08 So how are you factoring that and what kind of, if I were to look at next two, three years, you know, as a percentage of sales, be it quarterly, monthly or an annual basis, you know, this part of the business, can we entail like in the next three years, this could go to five six percent of your top line? Some trajectory and direction around that will give us some perspective, sir. No, I mean, your whatever you are mentioning, Shayk, I fully agree with you. To that line, I think we are working upon that. That's what I can say. I mean, it's very difficult to predict anything because we are evolving company. We are an emerging company, and we believe that there will be multi more new initiatives coming forward.

19:55 But as you know, we are quite helpful and whatever figures you mentioned, we internally are working such as that we will surpass it without mentioning any specific guidelines. So our internal working, our internal projections or internal business plans suggest that we will surpass whatever figures you mentioned in your originality. Okay. And sir, from a region perspective, can you please help give us some perspective, so if your current run rate in terms of revenue, how much is West Bengal contributing? How much are, say for example, the other parts of India contributing? And the new regions, how are you seeing them ramp up? Some perspective around your geographical expansion and the current growth contributors ourselves from a region perspective, that would be really helpful.

20:45 I'm very happy to announce that the product has been proven across the market. So from West Bengal this quarter we expanded to Odisha, Jharkhand, Bihar and Sattisgarh. From Noida, we expanded to Haryana and UP and Rajasthan are some notice we are covering. So 30 is right now out of West Bengal and all markets are giving very good response. And in terms of the growth, I must tell you that North is highest growing entity. This shows that this Tier two, Tier three, geographies and where as per IPM, if you see that heart and is having the highest growth rate.

21:31 This is happening because India is changing. I firmly thank to my internal team that you looked at IPM data, that 70, INR 80 crores new people who hit or to not taking medicine. You were talking about the Githo. So Githo is no more a subscription. It is a requirement of those INR crores people who are coming first time in the pharmacy shop to buy the medicine. So I'm very much hopeful for this new geography in Harkhand. We are planning to set up a new warehouse in Dachi, but now in Chattendarth. So these geographies, we will ramp up this year and next year very, very aggressively looking to our success in Assam. And as far as Assam is concerned, that is growing very fast and rapidly.

22:18 So the underpenetrated area has more scope of distribution and has more share of the G2. Sir, sir, I'll join back in queue. Thank you. Okay. Thank you. Our next question comes from the line of Disha with Sapphire Capital. Please go ahead. Hello? Am I audible, sir? Yes. You are audible, Disha. Yes. Thank you so much, sir, for this opportunity. So sir for retailers, Shasti, you mentioned that we had a gross margin of 10.8% and EBITDA closer to breakeven. For the Health Body platform, what the current gross margin and the EBITDA margin level for this quarter?

23:15 So actually the tell you that we are bidding. I must tell you what is the vision of our business. Sir, it's a bidding B2C business. So there are two ways of bidding B2C business. One is that we go digitally. Digitally, we have to expand the network, brand acquisition, technology. And if you go physically, we have to spend in retail shops and kill money into depreciation. So the depreciation model will show you the good EBITDA, but the case will not come. The success on that as per our model, we spent around 15% of the building the revenue. So suppose we build a INR 200 crores revenue in this year, then we have to invest around 15% of that means INR 30 crores. So if you see the current EBITDA loss of Sasasundar has been around 90% losses by virtue of technology buildup, that is number one. The technology buildup, I tell you the AI buildup is both for Retailer and Sasasundar.

24:12 AI have suggested that we are naturally look for this retailer and also we are building AI technology. And second is building revenue because we don't offer stocks for the entire building revenue comes in profit and loss. My humble request is that if you look Health X and if I'm investing Health X, don't look from EBITDA perspective. We are not an EBITDA positive company for next two, three years. And we neither look the EBITDA from perspective. So EBITDA is not our priority. Our priority is building a very, very large company without looking hardly EBITDA in the business. And we will build a solid business with a state cash flow without killing any money in depreciation. Thank you.

25:01 So sir, these gross margins, so okay, if not looking at EBITDA margin, for the gross margin I think you were at 9.2% this quarter. What will be the target for the entire year? The entire year we will be 8% plus gross margin. Sorry? 8% plus gross margin. And what is our eventual target of where do we want to take this number to, say, next to see here? As I said that it will run to 12% from 8% to 12% if you look the industry. See the gross margin is a function where we will be making the similar kind of gross margin where industry is working. Because the customer's pricing and supply we are buying from the same companies, we are supplying to the same customer. So gross margin is essentially for the industry.

25:50 The industry will go by that infrastructure is built in technology and capital efficiency. That is the only two factors which will differentiate in terms of return on capital employed, in terms of revenue and in terms of growth. So the gross margin will be the industry. The industry in B2B is operating around 12% and the B2C net of last mile retail shop expenses is also around 12% gross margin. So the gross margin is around 12% and we should achieve that at that scale. Okay. Okay. And just the last thing from my side. So we've seen revenues increasing, sir, but quarter on quarter, we've seen a bit decline in the other expenses. So what is that? So other expenses are not declining, as percentage of revenue that is declining.

26:35 As the revenue increases, your fixed cost remains same. So if you see the percentage that we decline, so that is a natural phenomena. As the scale goes, the fixed cost remains same and the expenses, that is how the company achieves that profitability going forward. Okay. Okay. That is it, sir. Thank you. Thank you. Thank you. Ladies and gentlemen, anyone who wishes to ask a question may press 1. Our next question comes from the line of Rohit with iThought PMS. Please go ahead. Good afternoon, sir. Good afternoon. I hope I'm audible. Yes. Yes. Sir, first of all, sorry. I'm a bit new to your company, so please pardon some questions which may be very basic.

27:25 So, sir, if I were to look at your business right now, so based on your presentation, you're saying that in the last financial year, you did $1.55 crores in and about thousand $1.25 crores in retail. So, I mean, so if you were to sort of double click on both these businesses for a minute, so can you sort of... So it seems from the outside that is a very different business from retailers, Shakti, in the sense that it has to... The customer acquisition is much more difficult, and and, also, you have much more bigger players with deeper pockets. So can you maybe just help us understand, like like, what is... So if you were to step back and then both these businesses are different, so how are you trying to build it?

28:19 First question is, is this different, or is this understanding even correct from your vantage point? These are different businesses, or is that not so? So if you can maybe help us understand the nuances of these two businesses in a bit more detail. No, your question is right. I mean, are but these are not two different businesses. This business is one part is the procurement, second part is fulfillment, third part is technology and fourth part is the last level of customers. So the first part, second part and third part, both the sales and the same. Now coming to B2C business that you addressed to, we have a very unique health body model, which are also retailers of the customer type, they are also small pharmacies. So we run a health body model. And we spend around 15% of building the revenue. So we have estimated that if we say with a 2,000 crore in the then we spend 15% of that INR 300 crore and at INR 2,000 crore company, we can make 5% revenue acquisition.

29:21 That is coming INR 100 crores per year. So by investing INR 300 crores, we make INR 100 crores per year. So that is 30% IRR on our investment. That is a pure mathematics of building success in the business. Having said that because that mathematics coming only because we need to invest only in one vertical, that is the customer acquisition and building brand. And then from a point of view, if you list, then you will see it will take certain amount of time, then it gives us the comfort. But I'm going to 2015, 2016, when Sasananda was over 80% business centered, we just started retail efficiency. Then the same Qsat analyst asked us that why are you bidding retail entity, who will buy without credit.

30:08 So you have a solid business of Sasasundar, why don't you expand, why don't you focus. So you just wait for one, two, three years. Once you start seeing the figures coming, then you get comfort out of it. No. Sure, sir. I mean, your scale up in retail is quite impressive in in No. No. No. That's not that impressive. The business is sold. You must appreciate that the business was 500 crores per year business in the same company. We sold Flipkart for 800 crores. And our company built capital out of that and out of the trading income of debt capital, we are investing. So we made good money out of the system generating. And right now also, I mean, at any point of time, business like system that is a contributing margin business can be sold by five, six times of your investment.

31:02 So I mean, it's a very beautiful business. And usually for bidding a very large scale business with large opportunities, you just need to look futuristic performance rather than putting into scale and see the linear progression. Right. Understood, sir. No, I mean, can you just maybe explain the Health Body model, what is the difference here? So The I mean, is it Health model we have explained in the slide also. The Health Body model is that if we don't directly deal with the customer. So we have put entirely in each pin code who don't hold inventory. So they run the store without inventory. So they book the customer's order on their shop and whatever order is coming in our app and website, etcetera, those are transferred to our central warehouse and we deliver to that Health So the last mile delivery, the compliance part, the last mile customer engagement part is being handled by that Health X So Health Party is an independent franchise partner who is like a retail store, like general retail store. So for us, that applies for the retailers, be it Health Party or a general retailer. So retail supply to general retailers, supply to company appointed to intelligent partner, name Health X But all our B2B business for us, the procurement is single, warehousing fulfillment center is single, tech team is single and management is single. And as I said,

32:32 we need to spend only 15% of the revenue, while if you see the other companies which are building in this company because they have to do everything together for B2C business, They have to spend five times more than success in the building. So that kind of liberalized why should we leave that leverage on table? So, sir, when you... So let's say... I'm sorry. Maybe this is a very stupid question. But so let's say... When you say the the franchises don't hold inventory, so how does the customer know that there is a franchisee... So that's money spending you do. So so is there an app on which you will have your franchise listed, the customer acquisition happens on your app, and the fulfillment happens by you at the back end. And based on the location, etcetera, to the tech, the nearest person will then get fulfilled. Is that how it is? Yes.

33:29 So this is a this is a hybrid model whereby somebody has started, then first thing he has a opening of his house. So opening he calls all his friends, all his relatives, so say they put together for tea, some other party. And from that, he starts selling 20 percussion to his friends. And then we build a health company in his area and he gets another 20 customers. Then we build a customer engagement program in this area, another 20, but it is 60 customers. Then we take reference and build 100 customers. And then that customer means three last sales per year. So I mean, this kind of data. So there is a twin effort. One is effort from Health Body, second is Health Com or digital capabilities and home ground activation.

34:15 So the Health Body has a center in that particular area that gives comfort and human touch to the customer also. So that is how it helps. Got it. Understood. And sir, this 7%, 8% of your revenue, which comes from finance is basically your treasury income? Yes. It is treasury income. Understood. Okay. Okay. So, sir, I think at this point of time, that's all from my side. I'll probably read more and come back for more questions. Maybe I'll reach out to the IR and set up a call. Thank you. Thank you. Our next question comes from the line of Amit Mehendale with Robo Capital. Please go ahead.

35:09 Thank you. Sir, my first question is, again, on the burn for this customer. I think we plan to, if I remember correctly, we had spent about INR 50 crores and we wanted to spend another 100 crores in FY 'twenty seven and 'twenty eight. I'm just wondering to kind of discuss a little bit on the rationale of spending INR 40 crores, 50 crores. My understanding there is that, you know, we don't require too much money for acquiring customers because largely a b to b to c model, and acquiring HealthBody is not very expensive. And from a customer side, the customer comes to us largely for discounts, you know, because we offer, say, 20, 22% discount on a... So so why... So that 50 crores that we are spending, what exactly does it do for the customer?

35:59 No, the large part is that some part of the money goes on building success in the brand. So we are advertising for success in the app in our territory. So that's how the brand is built. So one part is that. And second part is the tech team salary. So tech, we are building futuristically. As I said, retail is building a SaaS software called Retail Air, and we are building AI tool for customers based upon artificial intelligence tools. So these two salaries are being debited in the profit and loss account. And then see the expenses part is also not very easy. As you have seen in the presentation, we have given that we have started expanding in new territories like Bihar, Harkon, Purisa. So these we don't have any acquisition costs. We are not acquiring any existing revenue.

36:55 We are building revenue from our own resources. So we have to put sales team on the ground, so their expenses are debited in the new geographies like these geographies we have taken. We are building new warehouse in Noida, Guwahati, Lucknow, therefore, everywhere require team, everywhere require effort. So this 47% of growth, which will come there, there are two ways, either we pay huge premium to outsiders and buy out, then there will be capital allocation and the ROE will be compromised. But the analysts will be very happy to see the good amount of profit. But the capital is gone. And if I say I did that 10% of the cost, but the 10% cost will debited into profit and loss loan. And that will see the accounting as a burn. So if you look from my company, my company will look from the capital efficiency model that these earnings are generating revenue. See the differences in part of our company that we are a company which did not acquire any revenue, rather sold the revenue.

37:58 And we bought back the sales. We sold the revenue built on capital base and out of debt, treasury income building business. And we bought the capital rather than expended and diluted the capital. So these are the two differences, not a single penny or penny acquisition of a single revenue. Rather we sold 90% of revenue to Flipkart and then again building. And it still have gross debt largest quarter in this quarter. So these are the key differences. So these are the metric of capital efficiency, which you can rely only after four, five years once you see that how the capital efficiency measures in terms of shareholders' wealth. Right. I think definitely, I mean, it is definitely capital efficient. My just the point was that, you know, the branding or the technology calls that they're spending on AI. At least, currently, the customer doesn't want... I think my understanding is that customer comes to us for discounts.

38:55 But anyway, do you have numbers for how much we are spending for technology and how much we are spending for branding? That is the no, I myself pass this to I was an analyst at Microsoft when I was a new president of the And I was told to ask these things to enforce it, call that why are you investing in AI. So I mean these are normal, but we have to look at the future and we are looking the future. And not today, but after three years, all of a sudden you will find that, yes, the customer needs AI, the customer needs counseling. And it's not the customer needs AI, customer does not AI, customer needs counseling. The retailers are not required to adopt AI. The retailers are required to minimize the inventory and that minimization can be done by the automation of AI. Probably our retailer tools, they will not understand that this is an AI tool, but they will definitely understand that it decreases their inventory level, inventory investment from forty days to four days.

39:58 Think about a retailer does not need credit by automating his retailer, everything is automatically connected with retailer, the order percentage automatically and we have to invest 10 lakhs in inventory that comes to 2 lakhs in a month by adopting the new software. So this kind of technology is not about adoption of AI, but it is adoption of new specialty, and it automatically happens. All of a sudden, it happens. It happens in UPI in India, it happens in your capital market in 2020 adoption. So adoption becomes easy when consumers see the value of that in their daily life. Right, sir. Do I get is it possible to get split of that INR50 crores, INR60 crores born in technology branding and customer acquisition?

40:49 You can say that branding will be around 25% and technology Sir, I'm sorry to interrupt. We are not able to hear you, management. So breakup of this binding is somewhere around 25% to 30% is towards marketing and advertisement, while the 40% to 45% goes towards tech related cost. Right, sir. And my last point or the other suggestion is to provide P and L by business segments. That will be of great help. If you could split the p and l by and, you know, retailer separately, and then carve out the, you know, the one off cost, which are the which is the bond that we are doing. That will help us to understand the gross margins and EBITDA much better.

41:56 You. But right now, what is happening is that two third of the aggregate activities like procurement, fulfillment and take are so integrated. The carve out is not becoming possible. But we are working upon that. We are working upon take adaptability. Once it is ready, we'll start giving you the separate figures. Right. And if I may add just one last point. At least our understanding is that, you know, the burn, you know, of the market cap of the company is definitely... You know, if you compare with the scale at which we are growing as well as the cash that we have, you know, definitely, you know, there's a lot of scope for improvement on the market cap. But I guess the... You know, our understanding at least is that the burn, you know, for two years is delaying the, you know, eventual discovery...

42:49 Price discovery. So maybe, if you could just think about that, it will be helpful. So definitely, will do the appropriate disclosure, which helps to understand the investors, but we will expand the the so called funding, but we will continue to burn and continue to invest in technology because we are in the intensive stage, we have not reached out. So we will not stop for investment in technology, maybe more and more. So but definitely we will disclose it appropriately. Thank you, sir. Thank you. Our next question comes from the line of Ramesh with SJ Investments.

43:40 So I just wanted to understand, you mentioned in the past that like all last few calls, you mentioned that in a year or two, we'll probably reach EBITDA breakeven. While now we are extending the time line by two to three years. Like can exactly like sorry, I'll join the call. Could you explain why are we postponing that time line to a little later? We are not postponing. The retailer, we earlier said that we will achieve the breakeven this year. We are near to breakeven. And because the funding is coming by virtue of our B2C business, we have never said that taking together B2C, we will achieve the breakeven in the current year. Got it, sir. So can you exactly tell me what the exact burn is just for Sasasundar? I understand your tech cost and marketing cost. Could you just add the business, could you explain how much the burn is?

44:30 So we will as I said earlier, we have fully explained the methodology of the burning and we will figure out that to properly disclose segment wise investment from the time, then we are able to segregate the accounting things. Right now, all these are at integrated cost. But definitely, we will show you. Got it, sir. And coming to our warehouses, so we've had an option, like, we have had multiple geographies setting up capacities. And with land acquisition and building, usually, there are delays with the season and everything. Could you explain what... How are we, like, progressing forward with these warehouses? And where already we started? Like, what is the percentages we have done with? Capacity. So then Noida, we have already started in the number of this seventeenth we are starting the new warehouse only. So Noida is done and West Bengal is partly done.

45:28 Guwahati, we have expanded existing capacity by taking new warehouse on ten and seventy five thousand. This we are starting the construction in next six months' time. Others, we have started the construction. Patna and Guwati, we will Patna and Lucknow, we will start in the next two, three months. So these are the two years planning everywhere. So we take on rent and start immediately warehousing. And in the meantime, wherever we see the low good potentiality, we start building large capacity side by side so that we can shift for the next growth stage. So right now, Guavati is right now our priority in terms of converting the rental to our own facility, right? Yes.

46:19 Got it, sir. So in terms of the Cheeto response, could you explain like how the market has been taking it? Because I'm just trying to understand overall our brands, we are such as under Health X and Jito. They both have physical footprint as you know, and Jito also has more to it. So could you explain, are we able to communicate this to the channel properly or has been in harmony in terms of anything on the ground? No, no. This we have communicated very properly. So JITO revenue, as I said in my earlier comments, that we started in the last quarter and we sold INR 25 lakh rupees of product of Jitto in Q4 FY 'twenty six that rise to INR79 lakhs in current quarter. These are very case base figure is very low, but the growth is 200%.

47:05 So we see that good potentiality of Jito and good traction of Jito because it is the need of the consumer requirement, and this will grow. So is there a timeline in terms of all of them? Which timeline? So we've converted a few of the health parties into Cheetos, right? So is there any plan to convert all the health parties into Cheetos clinics, like JITO pharmacists? No, no. JITO, have already converted 19 health bodies into JITO and 25 are in pipeline. So around 50% of the health body will be converted into Jitro in next three months' time. And remaining are sell operate standalone Health Petty without Jitro. So these are the time lines for conversion of existing.

47:58 We are creating a new channel of pure play Jitro franchisee partners. We have invited partnership interest. So we are moving ahead in this year. But we have not set a time line for this, let the progress come on, and then we decide how to measure by time line. So do you have a broad... Thank you, Ramesh. I'm sorry to interrupt you, but you may please rejoin the queue for more questions. Thank you. Our next question comes from the line of Abhishek Singhal with Purputed Fund. Please go ahead. Sir, thanks for taking my follow on here. I just wanted to get a perspective on our readiness as far as our warehouses are concerned. So from what I understand, currently, way you are scaling your business, you know, your current infrastructure, what kind of top line per quarter can it sustain?

48:53 And, you know, how are you thinking about the back end from that perspective? And also, if you can add that perspective because there's a lot of automation you had done at your, you know, at your Calcutta, Kolkata warehouse. So have you replicated that kind of an automation across the board and something around the back end, if you can help us? And secondly, on this also, sir, if you can please help explain that this last mile delivery, are we having riders with us? How does that pan out? If you can just give us some perspective around that. Yes. So I must give you that perspective around that. So the first part I should take is the automation of the warehouses. So our existing warehouse infrastructure or fulfillment center infrastructure are ready to take up around 100% growth from the current level. So INR 2,500 crore to INR 300 crore, it means next year, 2028, we don't have any issue for the existing infrastructure.

49:55 After that, we require the massive infrastructure, explore the growth plans and going to the new territory. So for massive infrastructure, since we are into a pharmacy warehouse, whereby those are required licenses and those are required more hygiene and more capacity and more locality and more suitability. So we don't want to be dependent upon outside warehouses, but want to own the entire logistic and the fulfillment center. We want to make this also as an USP because pharmacy is not selling potato. These are very, very delicate things where we have to ensure that there is a proper atmosphere in the warehouse system, and we don't need to change because we are dealing with 50,000 SKUs.

50:44 So the expiry of the lease means transmission means huge losses. And we are into the continuous operations. So we can't afford to that. So that is how we are building. And the logistic, all the riders are on our payroll and with data, very nice change or full time employee and happy about it. Thank you very much. Thank you. Our next question comes from the line of Preet Shah with Kenya At Home. Please go ahead. Mr. Preet here. So firstly, many thanks for the strong numbers and for continuing to walk the talk. And the reason and ambition are remarkable for building such a futuristic AI enabled and forward looking company.

51:37 So thanks for that. The question that I have, what is the current capacity utilization and what is the maximum revenue can be achieved with existing infrastructure? And the second question is, are we facing any issues with the authority or permitting or anything for any upcoming warehouses? We are not facing any authority problem or any licensing problem of any of the warehouses. Those are fully compliant and issued. And as I said that from there are three parts of the fulfillment center capacity expansion. One is the pure existing, one is the existing plus that is already in side by side extension, you can say, and then third is building capabilities.

52:26 So existing, we are running about 90% of the capacity. But you see that existing plus sideway extension that will cover another 50% to 100% of our revenue for INR 3,000 crore revenue or existing plus side extension will be sufficient. Then we will need a massive amount of infrastructure development for building seamless infrastructure into a large company. And therefore, that we have invite the CapEx plan also, we have started building our new warehouse capability. But that will be a strong USP of our company to improve it. Okay. Got it. Got it, sir. Many thanks for this. And sir, last question, are we on track with this AB approval for this merger and demerger scheme?

53:15 Yes, yes. We are absolutely on track. We have started taking QCSIS from Stock Exchange and deploying them. We don't find any problem into anything so far. Okay. Thank you, sir. That's all from my many things. Thank you. Thank you. Ladies and gentlemen, we'll take the last question from Neelam Punjabi with Purview TT Ventures. Please go ahead. Thank you for the opportunity, and congratulations on some great set of numbers. So my first question is, you mentioned that 70% of our revenues is from West Bengal. So what's the current market share that we have in the region? And what is our target market share in the next three to four years?

54:04 So current market share in Calcutta and Vishnu Ghat should be around 34%. In next two, three years, we want to make it double from here. So say 7%. Got it. And then my second question is in the retail business out of 75,000 retailer pharmacies that we have as per the deck, How how many are active transacting pharmacies and what is our current wallet share right now? So active... I mean, active almost all registered do some in a period of one year, but if you say last thirty days, pure and super active, then 40,000 pharmacies are active in last thirty days.

54:56 Got it. And sir, what would be our average wallet share with these pharmacies? Somewhere around 2% would be the average wallet share with this pharmacy. Okay. And what's our target in terms of, you know, gaining additional wallet share from these existing pharmacies? Any number that you'll have in mind? The target is mainly the... As I said, that this AI enabled start, we are launching retail air. So once we launch the retail air, our entire target is to eliminate the inventory requirement at the pharmacy level. So suppose a retailer is keeping inventory of thirty days or target is to eliminate that from thirty days to five, six days because you guarantee the next delivery.

55:43 So we want to automate that and the wallet time we want to increase the double of the each retailer. So these things we will start working once we launch this retailer software, AI based start in the next quarter. Got it. That's helpful. Thank you so much and all the best. Thank you. Ladies and gentlemen, that was the last question for today. I now hand the conference over to the management for the closing remarks. Thank you, and over to you. Thank you, Faith. Thank you so much. Thank you. Ladies and gentlemen, on behalf of Health X Platform Limited, that concludes today's conference. Thank you for joining us, and you may now disconnect your lines. Thanks, Sonia, for arranging the call. Thanks, Sonia.

Follow Health X Platform Ltd into a list and get an email when it puts out news.

Companies on this call

More from Health X Platform Ltd